Zimmer Biomet Holdings (NYSE: ZBH) reported Q4 EPS of $2.11, $0.05 better than the analyst estimate of $2.06. Revenue for the quarter came in at $2.09 billion versus the consensus estimate of $2.08 billion.

Financial Guidance

There continues to be uncertainty around the ongoing impact of COVID-19. Therefore, the Company is currently unable to quantify the expected impact on its results of operations, financial condition and cash flows, which could be material, for full year 2021 and is not providing financial guidance at this time.

For earnings history and earnings-related data on Zimmer Biomet Holdings (ZBH) click here.